Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice

Antiviral Research

Volumn 93, Issue 3, 2012, Pages 346-353

  Shi, Jianzhong ^a   Wen, Zhiyuan ^a   Guo, Jing ^a   Zhang, Ying ^a   Deng, Guohua ^a   Shu, Yuelong ^b   Wang, Dayan ^b   Jiang, Yongping ^a   Kawaoka, Yoshihiro ^c   Bu, Zhigao ^a   Chen, Hualan ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION   (China)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

H1N1; H5N1; Influenza; Live attenuated vaccine

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ARTICLE; CD8+ T LYMPHOCYTE; CROSS REACTION; FEMALE; HUMORAL IMMUNITY; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEASONAL H1N1 INFLUENZA; SEASONAL INFLUENZA;

ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CHINA; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H2N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; SEASONS;

MUS; ORTHOMYXOVIRIDAE;

EID: 84863229371     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.01.001     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention (CDC) Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58:400-402.
2. Centers for Disease Control and Prevention (CDC) Update: influenza activity - United States, August 30, 2009-March 27, 2010, and composition of the 2010-11 influenza vaccine. MMWR. Morb. Mortal. Wkly. Rep. 2010, 59:423-430.
3. Belongia E.A., Kieke B.A., Donahue J.G., Greenlee R.T., Balish A., Foust A., Lindstrom S., Shay D.K. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J. Infect. Dis. 2009, 199:159-167.
4. Belshe R.B. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 2004, 103:177-185.
5. Chen H., Matsuoka Y., Swayne D., Chen Q., Cox N.J., Murphy B.R., Subbarao K. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 2003, 21:4430-4436.
6. Chen H., Subbarao K., Swayne D., Chen Q., Lu X., Katz J., Cox N., Matsuoka Y. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine 2003, 21:1974-1979.
7. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 2004, 59:1-15.
8. Dhere R., Yeolekar L., Kulkarni P., Menon R., Vaidya V., Ganguly M., Tyagi P., Barde P., Jadhav S. A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine 2011, 29(Suppl. 1):A16-A21.
9. Fan S., Gao Y., Shinya K., Li C.K., Li Y., Shi J., Jiang Y., Suo Y., Tong T., Zhong G., Song J., Zhang Y., Tian G., Guan Y., Xu X.N., Bu Z., Kawaoka Y., Chen H. Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. PLoS Pathog. 2009, 5:e1000409.
10. Fedson D.S. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J. Public Health Policy 2005, 26:4-29.
11. Girard M.P., Katz J., Pervikov Y., Palkonyay L., Kieny M.P. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine 2010, 28:6811-6820.
12. Girard M.P., Tam J.S., Assossou O.M., Kieny M.P. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 2010, 28:4895-4902.
13. Ilyicheva T., Susloparov I., Durymanov A., Romanovskaya A., Sharshov K., Kurskaya O., Ignashkina M., Shestopalov A. Influenza A/H1N1pdm virus in Russian Asia in 2009-2010. Infect. Genet. Evol. 2011, 11:2107-2112.
14. Jain S., Kamimoto L., Bramley A.M., Schmitz A.M., Benoit S.R., Louie J., Sugerman D.E., Druckenmiller J.K., Ritger K.A., Chugh R., Jasuja S., Deutscher M., Chen S., Walker J.D., Duchin J.S., Lett S., Soliva S., Wells E.V., Swerdlow D., Uyeki T.M., Fiore A.E., Olsen S.J., Fry A.M., Bridges C.B., Finelli L. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N. Engl. J. Med. 2009, 361:1935-1944.
15. Kuwano K., Scott M., Young J.F., Ennis F.A. HA2 subunit of influenza A H1 and H2 subtype viruses induces a protective cross-reactive cytotoxic T lymphocyte response. J. Immunol. 1988, 140:1264-1268.
16. Li Y., Shi J., Zhong G., Deng G., Tian G., Ge J., Zeng X., Song J., Zhao D., Liu L., Jiang Y., Guan Y., Bu Z., Chen H. Continued evolution of H5N1 influenza viruses in wild birds, domestic poultry, and humans in China from 2004 to 2009. J. Virol. 2010, 84:8389-8397.
17. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999, 223:77-92.
18. McMichael A.J., Gotch F.M., Noble G.R., Beare P.A. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 1983, 309:13-17.
19. Pearce M.B., Belser J.A., Houser K.V., Katz J.M., Tumpey T.M. Efficacy of seasonal live attenuated influenza vaccine against virus replication and transmission of a pandemic 2009 H1N1 virus in ferrets. Vaccine 2011, 29:2887-2894.
20. Perdue M.L., Bright R.A. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. Vaccine 2011, 29(Suppl. 1):A48-A50.
21. Raboni S.M., Stella V., Cruz C.R., Franca J.B., Moreira S., Goncalves L., Nogueira M.B., Vidal L.R., Almeida S.M., Debur M.C., Carraro H., dos Santos C.N. Laboratory diagnosis, epidemiology, and clinical outcomes of pandemic influenza A and community respiratory viral infections in Southern Brazil. J. Clin. Microbiol. 2011, 49:1287-1293.
22. Rotzschke O., Falk K., Deres K., Schild H., Norda M., Metzger J., Jung G., Rammensee H.G. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990, 348:252-254.
23. Rudenko L., van den Bosch H., Kiseleva I., Mironov A., Naikhin A., Larionova N., Bushmenkov D. Live attenuated pandemic influenza vaccine: Clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 2011, 29(Suppl. 1):A40-A44.
24. Schultz-Cherry S., Jones J.C. Influenza vaccines: the good, the bad, and the eggs. Adv. Virus Res. 2010, 77:63-84.
25. Shu Y., Yu H., Li D. Lethal avian influenza A (H5N1) infection in a pregnant woman in Anhui Province, China. N. Engl. J. Med. 2006, 354:1421-1422.
26. Suguitan A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., Luke C.J., Murphy B., Swayne D.E., Kemble G., Subbarao K. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 2006, 3:e360.
27. Tennis P., Toback S.L., Andrews E., McQuay L.J., Ambrose C.S. A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5years. Vaccine 2011, 29:4947-4952.
28. Vajo Z., Wood J., Kosa L., Szilvasy I., Paragh G., Pauliny Z., Bartha K., Visontay I., Kis A., Jankovics I. A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development. J. Virol. 2010, 84:1237-1242.
29. Van Kerkhove M.D., Mounts A.W., Mall S., Vandemaele K.A., Chamberland M., Dos Santos T., Fitzner J., Widdowson M.A., Michalove J., Bresee J., Olsen S.J., Quick L., Baumeister E., Carlino L.O., Savy V., Uez O., Owen R., Ghani F., Paterson B., Forde A., Fasce R., Torres G., Andrade W., Bustos P., Mora J., Gonzalez C., Olea A., Sotomayor V., De Ferrari M.N., Burgos A., Hunt D., Huang Q.S., Jennings L.C., Macfarlane M., Lopez L.D., McArthur C., Cohen C., Archer B., Blumberg L., Cengimbo A., Makunga C., McAnerney J., Msimang V., Naidoo D., Puren A., Schoub B., Thomas J., Venter M. Epidemiologic and virologic assessment of the 2009 influenza A (H1N1) pandemic on selected temperate countries in the Southern Hemisphere: Argentina, Australia, Chile, New Zealand and South Africa. Influenza Other Respi. Viruses 2011, 5:e487-e498.
30. Verity, E.E., Camuglia, S., Agius, C.T., Ong, C., Shaw, R., Barr, I., Middleton, D., Rockman, S., 2011. Rapid generation of pandemic influenza virus vaccine candidate strains using synthetic DNA. Influenza Other Respi. Viruses, in press. doi:10.1111/j.1750-2659.2011.00273.x.
31. Vesikari T., Fleming D.M., Aristegui J.F., Vertruyen A., Ashkenazi S., Rappaport R., Skinner J., Saville M.K., Gruber W.C., Forrest B.D. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006, 118:2298-2312.
32. Wang Z.G., Yi Y., Yang T.T., Liu X.L., Jiang F.C., Wang Z.Y., Chen J.M. Emergency surveillance of influenza during 2009 in the Chinese city of Qingdao. Influenza Other Respi. Viruses 2011, 5:53-59.
33. Weinfurter J.T., Brunner K., Capuano S.V., Li C., Broman K.W., Kawaoka Y., Friedrich T.C. Cross-Reactive T Cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog. 2011, 7:e1002381.
34. Wen Z., Ye L., Gao Y., Pan L., Dong K., Bu Z., Compans R.W., Yang C. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res. 2009, 84:215-224.
35. Xie H., Jing X., Li X., Lin Z., Plant E., Zoueva O., Yang H., Ye Z. Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS One 2011, 6:e16650.
36. Xu L., Bao L., Zhou J., Wang D., Deng W., Lv Q., Ma Y., Li F., Sun H., Zhan L., Zhu H., Ma C., Shu Y., Qin C. Genomic polymorphism of the pandemic A (H1N1) influenza viruses correlates with viral replication, virulence, and pathogenicity in vitro and in vivo. PLoS One 2011, 6:e20698.
37. Yang P., Duan Y., Wang C., Xing L., Gao X., Tang C., Luo D., Zhao Z., Jia W., Peng D., Liu X., Wang X. Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets. Vaccine 2011, 29:698-705.
38. Ye L., Lin J., Sun Y., Bennouna S., Lo M., Wu Q., Bu Z., Pulendran B., Compans R.W., Yang C. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 2006, 351:260-270.
39. Yu H., Feng Z., Zhang X., Xiang N., Huai Y., Zhou L., Li Z., Xu C., Luo H., He J., Guan X., Yuan Z., Li Y., Xu L., Hong R., Liu X., Zhou X., Yin W., Zhang S., Shu Y., Wang M., Wang Y., Lee C.K., Uyeki T.M., Yang W. Human influenza A (H5N1) cases, urban areas of People's Republic of China, 2005-2006. Emerg. Infect. Dis. 2007, 13:1061-1064.